SAGE Therapeutics Inc Q2 2021 Earnings Call Summary - Thomson StreetEvents

SAGE Therapeutics Inc Q2 2021 Earnings Call Summary

SAGE Therapeutics Inc Q2 2021 Earnings Call Summary - Thomson StreetEvents
SAGE Therapeutics Inc Q2 2021 Earnings Call Summary
Published Aug 03, 2021
21 pages (12506 words) — Published Aug 03, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of SAGE.OQ earnings conference call or presentation 3-Aug-21 12:00pm GMT

  
Brief Excerpt:

...A. Overview: Made tremendous progress over 1H21 on Co.'s mission to become the leader in brain health and a top-tier biopharmaceutical co. by transforming lives of patients with debilitating disorders of brain. 1. 2. With four positive data readouts in 1H21 and multiple potential catalysts pending in coming months, demonstrating that SAGE methodology is working, while executing across all three franchises: Depression. a. b. Neuropsych. c. Neurology. 3. Innovation in drug development requires a flexible and thoughtful approach with intention to provide the best patient impact and experience. a. SAGE has been innovating since Day 1, with goal of delivering medicines that matter, so people can get better sooner and stay better longer. B. Depression: In June, announced positive topline data from Phase 3 WATERFALL Study of zuranolone in patients with major depressive disorders (MDD). 1. Study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
SAGE Therapeutics Inc
Ticker
SAGE.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gavin Scott - JPMorgan Chase & Co, Research Division - Analyst : This is Gavin on for Cory. We're just curious about investor feedback that you've gathered since the topline WATERFALL readout? And what aspects of the data, if any, really stand out to the KOLs?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : We've seen the durability and response data within potential real-world usage of zuranolone, is there anything particularly from a safety perspective that might limit an immediate second 14-day course of therapy if that's required? I guess asked another way, this goes back to why a 14-day period was chosen in the first place and what's the longest continuous safe use period for zuranolone might be from a regulatory perspective?

Table Of Contents

SAGE Therapeutics Inc Corporate Call - ECNP Encore Presentation: Zuranolone Data Review Summary – 2021-10-04 – US$ 54.00 – Edited Brief of SAGE.OQ conference call or presentation 4-Oct-21 12:00pm GMT

SAGE Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2021-09-10 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 10-Sep-21 4:30pm GMT

SAGE Therapeutics Inc at Canaccord Genuity Growth Conference (Virtual) Transcript – 2021-08-11 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 11-Aug-21 12:00pm GMT

SAGE Therapeutics Inc at Wedbush PacGrow Healthcare Conference (Virtual) Transcript – 2021-08-10 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 10-Aug-21 4:00pm GMT

SAGE Therapeutics Inc Q2 2021 Earnings Call Transcript – 2021-08-03 – US$ 54.00 – Edited Transcript of SAGE.OQ earnings conference call or presentation 3-Aug-21 12:00pm GMT

SAGE Therapeutics Inc at Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit (Virtual) Transcript – 2021-07-13 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 13-Jul-21 6:25pm GMT

SAGE Therapeutics Inc at SVB Leerink CNS Forum (Virtual) Transcript – 2021-06-29 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 29-Jun-21 8:15pm GMT

SAGE Therapeutics Inc to Review Topline Results from the Phase 3 WATERFALL Study Call Summary – 2021-06-15 – US$ 54.00 – Edited Brief of SAGE.OQ conference call or presentation 15-Jun-21 12:00pm GMT

SAGE Therapeutics Inc to Review Topline Results from the Phase 3 WATERFALL Study Call Transcript – 2021-06-15 – US$ 54.00 – Edited Transcript of SAGE.OQ conference call or presentation 15-Jun-21 12:00pm GMT

SAGE Therapeutics Inc to Host Sage Science Spotlight: SAGE-718 In Depth Transcript – 2021-05-20 – US$ 54.00 – Edited Transcript of SAGE.OQ conference call or presentation 20-May-21 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "SAGE Therapeutics Inc Q2 2021 Earnings Call Summary" Aug 03, 2021. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2021-SAGE-Therapeutics-Inc-Earnings-Call-B14927279>
  
APA:
Thomson StreetEvents. (2021). SAGE Therapeutics Inc Q2 2021 Earnings Call Summary Aug 03, 2021. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2021-SAGE-Therapeutics-Inc-Earnings-Call-B14927279>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.